Potential IPF Gene Therapy Engages Target in 98% of Patients in Trial

Potential IPF Gene Therapy Engages Target in 98% of Patients in Trial

305905

Potential IPF Gene Therapy Engages Target in 98% of Patients in Trial

A single dose of the investigational oral therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF) achieved therapeutic target engagement of up to 98% in the lungs of patients, according to interim results of a Phase 2a trial. At all doses tested, the anti-fibrotic, or anti-scarring, therapy engaged its intended target by more than 50%, meeting a previously established threshold for predicted activity. “We believe the high target engagement levels seen after the administration of just a single…

You must be logged in to read/download the full post.